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Summary 
 
 Feedlot heifers (1,147) weighing 622 lb 
were used to evaluate the effects of implant 
strategy and Optaflexx administration.  Im-
plant treatments included Revalor2-200 
(R200) at arrival, or Revalor-IH at arrival and 
reimplantation with Finaplix2-H on day 58 
(RF).  Optaflexx (200 mg/heifer daily of rac-
topamine-HCl) was fed the last 28 days.  
Treatments were randomly assigned to 16 
pens.  After 182 days, heifers were slaugh-
tered, at which time carcass data were ob-
tained and semimembranosus muscle tissue 
was excised for RNA isolation.  Optaflexx 
administration significantly increased average 
daily gain (0.7 lb/day), feed efficiency (3%), 
hot carcass weight (10.5 lb), and ribeye area 
(0.42 square inches); decreased back fat thick-
ness; and improved yield grade.  There was no 
significant treatment effect on the expression 
of β1-adrenergic receptor (AR) mRNA, but 
there was a tendency for Optaflexx feeding to 
increase β2-AR mRNA concentrations.  For 
β3-AR mRNA, Optaflexx treatment numeri-
cally increased β3-AR mRNA in heifers im-
planted with R200, but significantly decreased 
expression in heifers implanted with RF.  Op-
taflexx also significantly decreased IGF-I 
mRNA in heifers implanted with RF, but nu-
merically increased IGF-I mRNA in heifers 
implanted with R200.  This data aids our un-
derstanding of the interaction between ster-
oidal implants and Optaflexx in feedlot heif-
ers.  Knowledge about the modes of action of 
various growth promotants will aid in design-
ing growth promotion strategies to enhance 
the efficiency of lean tissue deposition in feed-
lot cattle. 
 
Introduction 
 
 Optaflexx is an orally active β-agonist 
(ractopamine-HCl) approved for use in feedlot 
cattle in the United States.  It improves aver-
age daily gain, feed efficiency, carcass yield 
grade, hot carcass weight, and dressing per-
centage in feedlot steers when administered at 
the recommended daily dose of 200 mg/steer 
daily for the last 28 to 42 days of the feeding 
period.  Optaflexx administration has resulted 
in more variable results in heifers than in 
steers. Optaflexx works through the β-AR; 
there are three different subtypes of β-AR 
found in cattle, with the β2-AR being the most 
abundant in bovine skeletal muscle. Optaflexx 
is believed to elicit its response through bind-
ing to the β1-AR.  Binding to the β-AR leads 
to a cascade of events that is eventually fol-
lowed by an increase in muscle protein syn-
thesis and a decrease in protein degradation, 
which leads to an overall increase in lean  
tissue deposition.   
 
 
         
 
 1Optaflexx is a registered trademark of Elanco Animal Health, Indianapolis, IN. 
 2Revalor and Finaplix are registered trademarks of Intervet, Inc. 
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 Steroidal implants are also used in feedlot 
animals to improve average daily gain, feed 
efficiency, and total lean tissue deposition.  
One of the mechanisms through which in-
creased muscle growth is achieved with im-
plants is through increased production of mus-
cle insulin-like growth factor I (IGF-I).  Insu-
lin-like growth factor I is a potent stimulator 
of skeletal muscle growth.   
 
 The purpose of this trial was to investigate 
the effect of Optaflexx administration, in com-
bination with implant strategy, on feedlot 
heifer performance and the expression of mes-
senger RNA (mRNA) for IGF-I and the three 
β-AR subtypes. 
 
Experimental Procedures 
 
 One thousand, one hundred forty-seven 
heifer calves with an initial weight of 622 lb 
were randomly assigned to 16 pens.  One of 
four treatments was applied to each pen:  1) 
initial Revalor-200 (200 mg trenbolone ace-
tate/20 mg estradiol-17β) without or 2) with 
Optaflexx (200 mg/heifer daily of ractopa-
mine-HCl), 3) initial Revalor-IH (80 mg tren-
bolone acetate/8 mg estradiol-17β) and re-
implantation (day 58) with Finaplix-H (200 
mg trenbolone acetate) without or 4) with Op-
taflexx (200 mg/heifer daily of ractopamine-
HCl).  Heifers were fed three times daily and 
allowed ad libitum access to feed.  The finish-
ing diet consisted of 82.7% flaked corn, 5.1% 
alfalfa hay, 3.8% choice white grease, 2.5% 
cane molasses, and 5.9% of a finisher supple-
ment, on a dry matter basis.  Optaflexx was 
administered the last 28 days of the trial, and 
all heifers received melengestrol acetate (0.5 
mg/heifer daily).  Heifers were slaughtered 
after 182 days on feed, at which time 
semimembranosus muscle samples were ob-
tained.  For the gene expression work, two 
heifers per pen were analyzed.  Total RNA 
was isolated from muscle samples and reverse 
transcribed into complimentary DNA.  The 
complimentary DNA was generated for use in 
real-time, quantitative polymerase chain reac-
tion to evaluate the expression of mRNA for 
IGF-I, β1-AR, β2-AR, and β3-AR.   
 
Results and Discussion 
 
 Optaflexx administration significantly in-
creased average daily gain and feed efficiency 
(Table 1).  There was also a 10.5 lb increase in 
hot carcass weight, an increase in ribeye area, 
a decrease in back fat thickness, and improved 
yield grades in response to Optaflexx (Table 
1).  These responses to Optaflexx were similar 
to those typically observed for steers, and 
were larger than are often observed for heif-
ers.  These performance results are significant 
in that heifers have not always been observed 
to respond as well to the administration of  
Optaflexx as steers do. The response to Op-
taflexx in our study may be related to the im-
plant strategy used.   
 
 There was no significant effect of treat-
ments on the expression of β1-AR mRNA 
(Figure 1); there was a tendency for Optaflexx 
feeding to increase β2-AR mRNA (Figure 2).  
For the β3-AR mRNA, there was an implant 
by Optaflexx interaction, with Optaflexx lead-
ing to a numerical increase in β3-AR mRNA 
in heifers implanted with R200, but a signifi-
cant decrease in heifers implanted with RF 
(Figure 3).  There was also an implant by Op-
taflexx interaction on IGF-I mRNA, with Op-
taflexx leading to a significant decrease in 
IGF-I mRNA for heifers implanted with RF 
but numerical increases in IGF-I mRNA in 
heifers implanted with R200 (Figure 4).   
 
 The data from our study demonstrate that 
Optaflexx can have a positive effect on feedlot 
heifer performance and carcass characteristics.  
This may be related to the relative pay out of 
implants.  At the initiation of Optaflexx feed-
ing, the R200 group had been implanted for 
154 days and the RF group had been  
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implanted with Finaplix-H for 96 days.  Under 
these conditions, the potency of both implants 
at the time of Optaflexx initiation was likely 
negligible.   
 
 The performance response in our study 
was different than some others that have been 
unable to detect responses to Optaflexx in 
heifers.  Those studies often used heifers im-
planted closer in time to the initiation of Op-
taflexx feeding.  The differences between our 
results and those of others could suggest a 
possible interaction between implants and  
Optaflexx administration.  Results of our 
study also suggest that Optaflexx may in-
crease the expression of the β2-AR, which has 
been observed in some other studies per-
formed by our laboratory.  The data obtained 
from our study can aid in our understanding of 
the mechanisms of action of β-agonists used 
as growth promotants in the feedlot industry.  
It can also help in the understanding of the 
potential for interactions between the use of 
steroidal implants and β-agonists.  This 
knowledge will aid in our ability to improve 
efficiency of lean tissue deposition in beef  
cattle. 
 
 
 
Table 1.  Effect of implant and Optaflexx on performance and carcass characteristics of 
feedlot heifers 
 Treatment1 
Item RF RF+OPT R200 R200+OPT 
Pens 4 4 4 4 
Number of heifers 274 271 274 272 
Starting weight, lb 623 622 622 622 
Dry matter intake, lb/day 16.92 16.90 17.19 16.77 
Average daily gain, lba 3.04 3.14 3.10 3.14 
Feed:gaina 5.56 5.38 5.54 5.35 
Hot carcass weight, lba 758 771 764 772 
Ribeye area, square inchesa 14.46 14.84 14.60 15.02 
12th rib fat, inchesa 0.49 0.45 0.49 0.46 
Marbling score2 425 409 406 398 
Kidney, pelvic, and heart fat, % 1.97 2.00 2.01 2.03 
Calculated final yield gradea 2.61 2.45 2.61 2.43 
aOptaflexx effect, P<0.05. 
1RF = Revalor-IH initially plus reimplant with Finaplix-H at 58 days, OPT = Optaflexx fed  
during final 28 days of trial, R200 = Revalor-200 at trial initiation. 
2400 = Small.  
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Figure 4.  Insulin-like growth factor-I mRNA 
relative abundance in semimembranosus mus-
cle. Bars not bearing a common letter differ, 
P<0.05.  RF = Revalor-IH initially plus reimplant 
with Finaplix-H at 58 days, OPT = Optaflexx fed 
during final 28 days of trial, R200 = Revalor-200 
at trial initiation. 
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Figure 1.  β1-adrenergic receptor mRNA rela-
tive abundance in semimembranosus muscle. 
RF = Revalor-IH initially plus reimplant with 
Finaplix-H at 58 days, OPT = Optaflexx fed dur-
ing final 28 days of trial, R200 = Revalor-200 at 
trial initiation. 
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Figure 2.  β2-adrenergic receptor mRNA rela-
tive abundance in semimembranosus muscle.
RF = Revalor-IH initially plus reimplant with 
Finaplix-H at 58 days, OPT = Optaflexx fed dur-
ing final 28 days of trial, R200 = Revalor-200 at 
trial initiation. 
RF RF+OPT R200 R200+OPT
0
50
100
150
bc
ab
a
bcAr
bi
tra
ry
 u
ni
ts
, b
ill
io
ns
Figure 3.  β3-adrenergic receptor mRNA rela-
tive abundance in semimembranosus muscle. 
Bars not bearing a common letter differ, P<0.05. 
RF = Revalor-IH initially plus reimplant with 
Finaplix-H at 58 days, OPT = Optaflexx fed dur-
ing final 28 days of trial, R200 = Revalor-200 at 
trial initiation. 
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